Pacira BioSciences' Receivables - Net rose 1452.02% to $115.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $115.3 million, marking a year-over-year increase of 1452.02%. This contributed to the annual value of $113.3 million for FY2024, which is 734.02% up from last year.
Latest data reveals that Pacira BioSciences reported Receivables - Net of $115.3 million as of Q3 2025, which was up 1452.02% from $114.4 million recorded in Q2 2025.
In the past 5 years, Pacira BioSciences' Receivables - Net ranged from a high of $115.3 million in Q3 2025 and a low of $50.0 million during Q3 2021
Over the past 5 years, Pacira BioSciences' median Receivables - Net value was $98.4 million (recorded in 2022), while the average stood at $94.3 million.
As far as peak fluctuations go, Pacira BioSciences' Receivables - Net soared by 8703.55% in 2022, and later surged by 119.65% in 2023.
Over the past 5 years, Pacira BioSciences' Receivables - Net (Quarter) stood at $96.3 million in 2021, then grew by 2.16% to $98.4 million in 2022, then grew by 7.28% to $105.6 million in 2023, then grew by 7.34% to $113.3 million in 2024, then grew by 1.73% to $115.3 million in 2025.
Its last three reported values are $115.3 million in Q3 2025, $114.4 million for Q2 2025, and $104.7 million during Q1 2025.

Peer Comparison

Historic Data

Download Data 🔒

Date	Value